" class="no-js "lang="en-US"> The Michael J. Fox Foundation - Medtech Alert
Friday, August 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
The Michael J. Fox Foundation | Pharmtech Focus

The Michael J. Fox Foundation

About The Michael J. Fox Foundation

The Michael J. Fox Foundation
The Michael J. Fox Foundation for Parkinson’s Research is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.

Related Story

Central Nervous System

 ZyVersa Therapeutics and University of Miami Awarded a Grant From the Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation With IC100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology | Pharmtech Focus

ZyVersa Therapeutics and University of Miami Awarded a Grant From the Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation With IC100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology

July 28 2022

ZyVersa Therapeutics, Inc. (ZyVersa), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of […]

Central Nervous System

 FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutations | Pharmtech Focus

FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutations

May 25 2022

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem […]

Central Nervous System

 Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies | Pharmtech Focus

Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies

May 4 2022

Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today […]